[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:decipher-genomic-classifier":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Decipher Genomic Classifier",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07027124","Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer",[11],"Phase 2","RECRUITING","2026-08-26T02:17:56.243868Z","2026-07-05T05:32:16.731293Z"]